CNS Therapeutics - Global Strategic Business Report

Report
898 Pages
March 2024
Region: Global
Global Industry Analysts, Inc
ID: 4911753

The global market for CNS Therapeutics is estimated at US$122 Billion in 2023 and is projected to reach US$199 Billion by 2030, growing at a CAGR of 6.3% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

Market Growth: Understand the significant growth trajectory of the Neurodegenerative Diseases Therapeutics segment, which is expected to reach US$75.9 Billion by 2030 with a CAGR of 6.8%. The Mental Health Therapeutics segment is also set to grow at 6.1% CAGR over the next 8 years.
Regional Analysis: Gain insights into the U.S. market, estimated at $49.2 Billion in 2023, and China, forecasted to grow at an impressive 9.8% CAGR to reach $19.9 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global CNS Therapeutics Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global CNS Therapeutics Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global CNS Therapeutics Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as Abbott Laboratories, Inc., AbbVie, Inc., Acumen Pharmaceuticals, Inc., and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 353 Featured):

Abbott Laboratories, Inc.
AbbVie, Inc.
Acumen Pharmaceuticals, Inc.
Alexza Pharmaceuticals
A. Menarini Industrie Farmaceutiche Riunite Srl
AC Immune SA
Addex Therapeutics
Ache Laboratorios Farmaceuticos SA
4D pharma plc
Acadia Pharmaceuticals, Inc.
AB Science SA
ABL Bio, Inc.
AcelRx Pharmaceuticals
Aarti Drugs Ltd.
Abion

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Central Nervous System (CNS) Therapeutics: A Prelude
Global Central Nervous System Therapeutic Market Glimmers with Robust Health
Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market
Developed Markets to Maintain their Dominance
Developing Market to Drive the Market Momentum, Asia-Pacific to Exhibit Fastest Growth
Neurodegenerative Disease & Mental Health: Lifeline Segments of CNS Therapeutics Market
CNS Cancer Segment to Post Fastest Growth
Competition
CNS Therapeutics - Global Key Competitors Percentage Market Share in 2023 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
Recent Market Activity
MARKET ANALYSIS BY THERAPEUTIC CATEGORY
Anti-Epilepsy Market
Regional Landscape
Developed Countries Account for a Major Share of Epilepsy Treatment
Developing Countries Struggle with Low Treatment Rates
Disease Overview
Epilepsy Incidence by Type (2022E): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy
Symptomatic Epilepsy Incidence by Type (2022E): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy
Global Epilepsy Etiology: Percentage Breakdown by Type for 2022E
Drugs for Epilepsy
Market for Epilepsy Drugs
Regional Landscape
Developing Countries Struggle with Low Treatment Rates
High Unmet Needs Offer Scope for Market Growth
Treatment
Anti-Epileptic Drugs (AEDs) by Generic Name and Brand Names
Leading Anti-Epileptic Drugs
Leading Anti-Epileptic Drugs and Their Mechanism of Action
Patent Expiries of Major Anti-Epilepsy Drugs
FDA's New Policy for AED Drugs to Bolster Market Growth
AAN Updated Guidelines on New AEDs Use for Treating New Onset Epilepsy (2019)
Select Currently Available Epilepsy Drugs
Innovative Drugs Needed for Better Treatment Compliance
Abounding Potential for NCEs
A New Research Demonstrates Effectiveness of Gluconate in Treating Neonatal Seizures
FDA Approves Epidiolex (Cannabidiol) - First Drug for Treating Dravet Syndrome and Lennox-Gastaut Syndrome
Refractory Childhood Epilepsy & Pregnancy Epilepsy - Major Concerns
Recent Approvals for Childhood Epilepsy
Review of Anti-Epilepsy Drugs
Vimpat®
Keppra®
Lamictal
Tegretol®
Sabril®
Perampanel
Zonegran®
Topamax®
Trileptal®
Neurontin®
Lyrica®
Depakine®
Anti-Alzheimer's
Market Overview
Global Alzheimer's Prevalence by Age Group
Alzheimer's Phase III Completed Studies
Alzheimer's Phase III Ongoing Studies
Treatment for Alzheimer's
Select Leading Drugs for Alzheimer's Disease by Drug Category
Patent Expiries of Leading Alzheimer's Drugs
Alzheimer's Drugs: A Market Plagued with Failures
Promising Compounds with Silver Lining
Updated FDA Standards Make Way for Increased Alzheimer’s Drug Testing
Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
Novel Drug Delivery Method to the Brain Discovered
Alzheimer's Association Provides Grant to Longeveron
A Review of Select Anti-Alzheimer's Drugs
Aricept
Exelon
Reminyl
Ebixa
Namenda
A Review of the Alzheimer's disease
Alzheimer’s Effect on Brain
Causes for Alzheimer's
Who Are at Risk?
Prevalence of Alzheimer’s Disease
Diagnosis of Alzheimer’s
Anti-Parkinson's
Market Overview
Nourianz, An Add-on Medication for Treating Episodes of Parkinson’s Disease Secures FDA Approval
Recent Approvals
Novel Drug and a New Delivery Method for Restoring Brain Cells in People Suffering from PD
Xadago - Add-On Therapy for Parkinson’s Disease
NUPLAZID® - The First and the Only Approved Drug for Psychosis related to Parkinson’s disease
Select Parkinson’s Phase III Completed Studies: As of June 2022
Select Parkinson's Ongoing Phase III Studies: As of June 2022
Select Anti-Parkinson’s Drugs
Levodopa
Dopamine Agonists
Mirapex
GSK Discontinues Requip for PD and RSL Treatment
A Review of the Parkinson’s Disease
Prevalence
Symptoms
Causes
Diagnosis
Anti-Depressants
Market Overview
Anti-Depressant Market: Percentage Share Breakdown by Depressive Disorder Type
Anti-Depressant Treatment
Select Antidepressants Drugs
Zoloft (Sertraline)
Cymbalta®
Prozac (Fluoxetine)
Effexor (Venlafaxine)
Paxil
Wellbutrin (Bupropion)
Select Pipeline Drugs in Phase III for Depressive Disorders: As of June 2022
A Review of Depression
Prevalence of Depression
Causes of Depression
Types of Depressive Disorders
Available Treatment
Tricyclic Antidepressants
Monoamine Oxidase Inhibitors
Lithium Salts
Working of Antidepressants
Ranking of Antidepressants in Terms of Efficacy
Types of Antidepressants
NMDA Receptor Antagonists
NMDA Receptor (NMDAR)
NMDA Receptor Agonists
Acetylcholinesterase Inhibitors
Selective Serotonin Reuptake Inhibitors (SSRIs)
Workings of SSRIs
Safety Levels of SSRI Drugs
Adverse Effects of SSRI
Serotonin Noradrenaline Reuptake Inhibitors (SNRIs)
Other CNS Disorders (Multiple Sclerosis, Attention Deficit Hyperactivity Disorder (ADHD), and Insomnia)
Multiple Sclerosis (MS)
List of Approved Drugs for MS
Patent Expiration Date/Year of the Major MS Drugs
New Approvals
Novartis Receives FDA Approval for Mayzent for Use in Multiple Sclerosis
Mavenclad Gains FDA Approval
Celgene Files NDA for Ozanimod
Ocrevus - The First Approved Drug for Primary Progressive Multiple Sclerosis (PPMS)
Multiple Sclerosis: Pipeline Analysis
Select Pipeline Drugs in Phase III for Multiple Sclerosis: As of June 2022
A Review of Multiple Sclerosis (MS)
Types of Multiple Sclerosis
Clinical Subtypes of Multiple Sclerosis (MS)
Prevalence of MS
Causes of MS
Myths Surrounding Multiple Sclerosis
Symptoms of MS
Diagnosis of MS
Insomnia
Overview
List of Approved Drugs for Insomnia
Select Pipeline Drugs for Insomnia: As of June 2022
Zolpidem
Eszopiclone
A Review of Insomnia
Prevalence of Insomnia
Therapies for Insomnia
CNS Pain Management
Market Overview
Treatment
Drugs Indicated for Pain Management
Regional Overview
Players
Combination Therapies Gain Prominence
Key Trends in Chronic Pain Management
Neuropathic Pain Management: Market with High Potential
Select Phase III Ongoing Studies for Neuropathic Pain
Lyrica's Generics Gain FDA Approval
Migraine Market: A Core Vertical in CNS Pain Management
Migraine Care: Select Patent Expiries (2013-2015)
Migraine Completed Phase III Studies
Migraine Ongoing Phase III Studies
Select Pain Management Drugs
Flupirtine
Lyrica
Oxycodone
Nucynta ER
Metabotropic Glutamate Receptors (mGluRs)
New Pain Management Drugs
Novartis Presents New Data for Aimovig
Reyvow, Eli Lilly's Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
Three New Migraine Drugs Obtain FDA Approval
Eli Lilly's Emgality Receives FDA Approval
An Insight into Mental Health Prevalence and Addressal
Global Prevalence of Mental Health Disorders by Type
Anti-Psychotics
Market Overview
Leading Atypical Antipsychotics for the Treatment of Schizophrenia
Select Pipeline Drugs in Phase III for Schizophrenia: As of June 2022
Select Pipeline Drugs in Phase III for Bipolar Disorder: As of June 2022
Select Anti-Psychotic Drugs
Zyprexa
Seroquel
Abilify
Clozaril
Risperdal
Risperdal® Consta®
Geodon
Invega Sustenna
Saphris
Latuda
A Review of Anti-Psychotics
Indications of Antipsychotics
An Effective Adjunctive Therapy
Off-label Uses
Efficacy - Marred by Lack of Evidence Base
Types of Antipsychotics
Difference between Typical and Atypical
Atypical Antipsychotics Up Against Typicals
Side Effects of Antipsychotics
Symptoms of Antipsychotics Withdrawal
Bipolar Disorder
Symptoms of Bipolar Disorder
Mood Episode - A Major Symptom
Manic Episode Vs Depressive Episode
Causes of Bipolar Disorder
Types of Bipolar Disorder
Co-morbidities of Bipolar Disorder
Schizophrenia
Prevalence by Gender
Symptoms of Schizophrenia
Causes of Schizophrenia

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Incidence of Neurodegenerative Conditions
Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Increased Spending on Prescription Drugs Bodes Well for the CNS Therapeutics Market
Rising Healthcare Expenditure to Boost CNS Therapeutics Market
World Healthcare Expenditure (In US$ Trillion) for the Years 2017, 2019, 2021 & 2023
Per Capita Healthcare Expenditure (in $) by Select Countries for 2018
Growing Middle Class Population in Emerging Regions to Spur the Market
Global Middle Class Population (In Million) by Region for the Years 2020, 2025 and 2030
Global Middle Class Spending (US$ Trillion) by Region for the Years 2020, 2025, 2030
Developments in CNS Drug Delivery Technologies Bode Well for the CNS Drugs Market
Understanding of BBB Cell Biology & Its Positive Impact on Epilepsy Drugs: A Case-in-Point
Pharma Companies: Seeking New Tools to Offset Pressure on Drug Pipelines
Awareness Campaigns Launched by Pharma Companies to Benefit the Market…
Music and Memory Programs Positively Impact Alzheimer’s Disease (AD) and Related Dementia (ADRD) Patients
New Method to Isolate Active Compounds Related to Alzheimers from Plant Medicines
Influx of New Products & Strong Pipeline
CNS Pharmaceuticals Secures FDA Approval for Protocol Amendment to Trial Targeting GBM Treatment
Central Nervous System Therapeutics: From Bleak to Bright Outlook
Novel Drug-Delivery Options
Advances in Drug Discovery Methods for Rare Diseases
Market Restraint: Complex Nature of R&D
Ongoing Research on Psychedelics Substances Pave Way for Ensuring Timely Treatment for Various Mental Illnesses
Advent of Advanced Disease Pathology and Diagnostics Techniques Facilitate Medical Professionals in Diagnosing Mental Illness at an Earlier Stage
Introduction of Innovative Technologies Fuel Demand for Biological Medicines

4. GLOBAL MARKET PERSPECTIVE

Table 1: World CNS Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
Table 2: World Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 3: World Historic Review for CNS Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 4: World 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
Table 5: World Recent Past, Current & Future Analysis for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 6: World Historic Review for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 7: World 16-Year Perspective for Neurodegenerative Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 8: World Recent Past, Current & Future Analysis for Mental Health by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 9: World Historic Review for Mental Health by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 10: World 16-Year Perspective for Mental Health by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 11: World Recent Past, Current & Future Analysis for Neurovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 12: World Historic Review for Neurovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 13: World 16-Year Perspective for Neurovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 14: World Recent Past, Current & Future Analysis for Cns Trauma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 15: World Historic Review for Cns Trauma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 16: World 16-Year Perspective for Cns Trauma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 17: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 18: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 19: World 16-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 20: World Recent Past, Current & Future Analysis for Cns Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 21: World Historic Review for Cns Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 22: World 16-Year Perspective for Cns Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 23: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 24: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 25: World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES

Market Facts & Figures
Aging Population: A Strong Demographic Driver
North American Elderly Population by Age Group (1975-2050)
The Largest CNS Therapeutics Market Globally
Patent Expiries of Leading CNS Drugs in the US
Focus on Select Markets
Alzheimer’s Market
Anti-depressant Drugs
Usage of Antidepressants Surges in the US
Anti-Epilepsy Market
Epilepsy - A Major Concern for the Healthcare Industry
A Glance at Epilepsy Statistics
Anti-Epilepsy Drugs
The US Epilepsy Market: Patent Expiry of Select Major Drugs
Epilepsy in Children
Growing Competition from Generics
Pain Management Market
Consumers in the US Seek Different Options for Chronic Pain Management
Neuropathic Pain Market
Anti-Psychotic Drugs Market
Mental Illnesses - Epidemiology
Facts & Figures
Lifetime Prevalence (%) of Bipolar Disorder in the US Population by Age Group
Popular Antipsychotic Drugs in the US
The US Anti-Psychotic Drugs Market by Indication (2022E): Percentage Share Breakdown of Value Sales
Surging Off-label Prescriptions
Generics Occupy Front Seat
Rising Antipsychotic Use among Children - A Cause of Concern
Market Analytics
Market Analytics

CANADA

CNS Diseases: Facts & Figures

JAPAN

CHINA

China: The Primary Market for CNS Drugs in Asia-Pacific
Select Anti-Schizophrenia Drugs Available in China
Other Available CNS Drugs in China

EUROPE

Market Facts & Figures
Pain Management Market
Neuropathic Pain Market Witnesses Foray of Generics
Anti-Psychotics Market
Demand for Antipsychotics for Bipolar Disorder Upbeat
Market Analytics

FRANCEGERMANY

ITALY

Market Snapshots

UNITED KINGDOM

NICE Recommendations on CNS Therapeutics

SPAINRUSSIAREST OF EUROPE

ASIA-PACIFIC

India & China Offer Significant Growth Opportunities
Growing Antipsychotics Market in Asia

AUSTRALIAINDIASOUTH KOREAREST OF ASIA-PACIFICLATIN AMERICAARGENTINABRAZILMEXICOREST OF LATIN AMERICAMIDDLE EASTIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTAFRICAIV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Abbott Laboratories, Inc.
AbbVie, Inc.
Acumen Pharmaceuticals, Inc.
Alexza Pharmaceuticals
A. Menarini Industrie Farmaceutiche Riunite Srl
AC Immune SA
Addex Therapeutics
Ache Laboratorios Farmaceuticos SA
4D pharma plc
Acadia Pharmaceuticals, Inc.
AB Science SA
ABL Bio, Inc.
AcelRx Pharmaceuticals
Aarti Drugs Ltd.
Abion

Table Information

Report Attribute	Details
No. of Pages	898
Published	March 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 122 Billion
Forecasted Market Value ( USD ) by 2030	$ 199 Billion
Compound Annual Growth Rate	7.2%
Regions Covered	Global

PURCHASE OPTIONS

Single User License PDF

1 - 10 User License PDF

Enterprise License PDF

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5407EUR$5,600USD£4,578GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€10273EUR$10,640USD£8,699GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€16220EUR$16,800USD£13,735GBP

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 353 Featured):

MarketGlass Platform

Table of Contents

Companies Mentioned (Partial List)

Table Information

Related Topics

Related Reports

Global Central Nervous System Therapeutic Market

Global Central Nervous System Therapeutics Market Report by Disease, Application, and Region 2024-2032

Global Anti-Epileptic Drugs Market: Analysis By Drug Generation, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028

Global Central Nervous System Drugs Market by Drug Classes (Analgesics, Anesthetics, Anti-Epileptics), Diseases (CNS Trauma, Infectious Diseases, Mental Health), Drug Type, Distribution Channel - Forecast 2024-2030

Global Central Nervous System Therapeutics Market by Diseases (Cancer, Degenerative Diseases, Infectious Diseases), Drug Class (Analgesics, Anesthetics, Anti-Epileptics), End-Users - Forecast 2024-2030

About the Central Nervous System Drugs Market